AzTrials
AzTrials

Acute Ischemic StrokePhase 3NCT05073159

Head-of-Bed Positioning in Large Artery Acute Ischemic Stroke

A Phase 3 study testing Allocating head-of-bed position in people with Acute Ischemic Stroke, run by National University of Singapore at 2 sites in Singapore.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Positioning of the patient with hyperacute large artery ischemic stroke (IS) is an important, yet understudied aspect of care that could impact the course of treatment and ultimately clinical outcome. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Acute Ischemic Stroke
What is being tested?
Allocating head-of-bed position
Could I receive a placebo?
No, everyone receives an active treatment
How many people
182 participants
Where
2 sitesSingapore
Study dates
11 Feb 2020to 30 Apr 2024
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Ischemic stroke symptoms consistent with large artery occlusion
  • Baseline non-contrast head CT (or MRI) negative for hemorrhage or mass- effect
  • Evidence of arterial occlusion on standard of care CT angiography or MR angiography or NIHSS 10 or more points
  • Alberta Stroke Program Early Computed Tomography Score [ASPECTS] >6
  • Patients treated with IV-tPA, mechanical thrombectomy or both
  • Pre-stroke baseline modified Rankin Score (mRS) <1
  • Ability to enrol, randomize and begin the intervention within the Emergency Department

Who cannot join

  • • Pregnancy or suspicion of pregnancy
  • Evidence or suspicion of vomiting any time prior to consent which could predispose to aspiration pneumonia and therefore confound determination of protocol safety
  • Evidence of evolving malignant infarction on admission noncontrast CT (or MRI)
  • Need for intubation with mechanical ventilation, or non-invasive ventilatory support with either bi-level positive airway pressure (BiPAP) or continuous positive airway pressure (CPAP)
  • Inability to tolerate zero-degree positioning due to congestive heart failure, preexisting pneumonia, chronic obstructive pulmonary disease, or other medical condition
  • Admission chest radiograph positive for pleural effusion, pulmonary edema, pneumonia, or other pulmonary condition that may confound determination of protocol safety
  • Abnormal breath sounds on that may confound determination of protocol safety

Trial locations and contacts

2 sites in 1 country.

VIJAY K SHARMA, MD contact

91389555

mdcvks@nus.edu.sg

Singapore2 sites, 2 recruiting
  • Division of Neurology, National University Hospital

    Singapore, 119074

    Vijay K Sharma, MD, 67795555 ext. 6190, mdcvks@nus.edu.sg

    Lily Wong, RN, 67795555 ext. 2517, lily_wong@nuhs.edu.sg

    Recruiting
  • National University Hospital

    Singapore, 119228

    Lily YH Wong, RN, 67722517, lily_wong@nuhs.edu.sg

    Recruiting

Other trials in Singapore

About this study

Positioning of the patient with hyperacute large artery ischemic stroke (IS) is an important, yet understudied aspect of care that could impact the course of treatment and ultimately clinical outcome. Positioning with the head of bed (HOB) at 0-degree has been shown in small studies to increase cerebral blood flow across arterial occlusion in hyperacute large artery IS, leading to clinical improvement in stroke symptoms. However, this position is believed to increase the risk of aspiration pneumonia. In this randomised clinical trial, the investigators aim to evaluate whether use of 0-degree HOB positioning is associated with clinical stability in hyperacute IS. Investigators hypothesise that patients with large artery occlusions placed in a 0-degree HOB position will experience less early neurologic deterioration within the first 24 hours, than those in the 30-degree or more HOB elevation group. The study aims to confirm the safety of 0-degree-HOB positioning in a large, generalizable sample of hyperacute large artery IS patients. In this randomised trial, patients presenting to the study centers and eligible for intravenous thrombolysis, with (if presenting within 4.5 hours of symptom-onset) or without (presenting between 4.5 to 16 hours of symptom-onset) mechanical thrombectomy. Eligible patients would be randomised to either a zero-degree HOB or an HOB of 30-degree or more. Impact of HOB position on neurological status would be evaluated with serial NIHSS scores. Cerebral hemodynamics would be monitored by transcranial Doppler ultrasonography. Validated criteria would be used to diagnose pneumonia. Functional outcome would be measured by modified Rankin scale (mRS) where the score of 0-2 describe good functional recovery. SPSS version 20 would be used to analyse the data. The trial would provide clinical and hemodynamic data to determine the optimal HOB position in patients with large artery acute ischemic stroke.

Read the detailed description

Positioning of the patient with hyperacute IS is an important, yet understudied aspect of care that could impact the course of treatment and ultimately clinical outcome. Positioning with the head of bed (HOB) at 0-degree has been shown in small studies to increase cerebral blood flow across arterial occlusion in hyperacute large artery IS, leading to clinical improvement in stroke symptoms. On the other hand, small studies have also documented clinical symptom worsening in IS patients when the HOB was elevated to 30-degree or higher.

A recent large cluster randomized trial (HeadPoST) attempted to determine the optimal head position in acute IS, but failed to enrol the patient cohort for which 0-degree head positioning may be beneficial. Findings from HeadPoST have been debated by the stroke neurologists due to some design flaws and enrolment of inappropriate patients to answer this question. In fact, HeadPoST has become a catalyst for conducting a high quality head positioning research in hyperacute large artery IS to definitively answer the question of how best to manage these highly vulnerable patients to ensure stability and prevent symptom worsening.

Mechanisms proposed for clinical improvement at 0-degree-HOB include favorable gravitational arterial flow conditions, recruitment of collateral vessels, and in the case of intravenous thrombolysis, improved clot-lytic interactions augmenting arterial recanalization. Collectively, these mechanisms may support the argument that 0-degree-HOB positioning should be among the first steps taken in large artery hyperacute IS patient management.

This efficacy study aims to determine if 0 degree-HOB positioning in hyperacute IS prevents neurological symptom worsening in large artery occlusion patients. The study will achieve these goals through use of a novel protocol enabling enrolment of consecutive large artery occlusion patients while maintaining compliance with management specified by the guidelines.

This phase III study will utilize a prospective randomized outcome-blinded evaluation (PROBE) approach enrolling consecutive hyperacute large artery IS patients to determine if use of 0-degreeHOB positioning is associated with greater clinical stability.

Suspected acute IS patients admitted to the study center(s) will undergo guideline-supported standard of care stroke team emergency response procedures, including assessment/ stabilization of airway, breathing, circulation with immediate transport for imaging. Continuous portable ECG monitoring and nasal canula oxygen will be established in CT (or MRI), and IV access will be obtained with STAT blood draw; point of care testing will be conducted immediately before STAT non-contrast CT (or MRI) with CTA (or MRA). The NIHSS will then be scored by the stroke team, followed by standard of care placement of a continuous pulse oximetry sensor, and completion of a rapid/detailed history/physical exam. Patients eligible for treatment with IV-tPA will have drug administered, and standard of care admission upright chest x-ray (CXR) will then be performed. Subjects meeting inclusions without exclusions will then be consented, randomized, and placed in the assigned HOB position, signaling the beginning of the monitoring phase of the intervention.

Patients will be transferred to the catheterization lab for mechanical thrombectomy (MT) once the team is ready for the procedure. Thrombectomy requires transfer from the ED to catheterization lab, with 0-degree-HOB positioning commencing immediately prior to groin puncture constituting the end of the head positioning phase of the protocol. Thrombectomy patients are extremely likely to benefit from 0-degree-HOB positioning because the procedure is only performed in patients without evidence of completed infarction. This novel protocol will capture serial NIHSS over the period before thrombectomy begins, allowing us to better understand how to maintain stability in this high risk vulnerable population.

Enrolled patients will be randomized to either 0-degree-HOB or 30-degree (or more) HOB positioning, and will undergo serial NIHSS assessments every 15mins +/- 5 mins while awaiting start of the thrombectomy. The patients will also undergo 24-hour ± 6hrs, 72hrs ± 12hrs discharge/7day, and 90-day +/- 14 days outcome monitoring, but these will be collected for exploratory purposes only. The NIHSS and mRS will be performed by credentialed members of the team. In addition to the chest X-Ray, blood will be drawn after obtaining the consent for HSCRP and Procalcitonin levels, primarily to substantiate the diagnosis of pre-hospital arrival chest infection, if any.

To assure balance in the treatment group throughout the course of enrolment, the investigators will use block randomization with a block size of 4 and an allocation ratio of 1:1. This scheme only shows the random assignment for a single given participant. Future assignments cannot be predicted by study personnel, and this effectively mitigates the risk for selection bias.

Being tested
Allocating head-of-bed position
Medical subject headings
Ischemic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Allocating head-of-bed positionBiological

    Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position

Study groups in NCT05073159
Study groupRoleWhat they receive
0 degree Head-of-Bed (HOB) positionActive comparatorPatients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
Receives: Biological: Allocating head-of-bed position
Elevated (30-degree or more) head-of-bedActive comparatorPatients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
Receives: Biological: Allocating head-of-bed position

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. National Institute of Health Stroke Scale (NIHSS) change (higher change means more improvement) at day-7 and modified Rankin Score (mRS) at day-7

    Investigators will analyze the data by dichotomized modified Rankin Score (mRS) 0-2 (good functional outcome) versus 3-6 (poor outcome) as well as mrs 0-1 (excellent outcome) versus mRS 2-6 (unfavorable outcome) as well as ordinal shift across the range of mRS 0-6

    Measured: day-7

  2. National Institute of Health Stroke Scale (NIHSS) change (higher value indicate more improvement) at day-90 and modified Rankin Score (mRS) at day-90

    Investigators will analyze the data by dichotomized mRS (0-2 as good functional outcome versus 3-6 as poor outcome), mRS (0-1 as excellent functional outcome versus 2-6 as unfavorable outcome) as well as ordinal shift across entire range of mRS 0-6.

    Measured: day-90

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2021
  2. Study start11 Feb 2020
  3. Primary completion30 Mar 2024 (estimated)
  4. Study completion30 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Controlled study
Masking
None (open label)
Enrolment
182 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05073159
Sponsor's protocol ID
NMRC/CIRG/18nov-0012
Status last verified
Nov 2023
First submitted
17 Sep 2021
Last updated
15 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD would be shared after completion of the study upon reasonable request

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Allocating head-of-bed position in people with Acute Ischemic Stroke, run by National University of Singapore at 2 sites in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact VIJAY K SHARMA, MD (91389555, mdcvks@nus.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

National Institute of Health Stroke Scale (NIHSS) change (higher change means more improvement) at day-7 and modified Rankin Score (mRS) at day-7 (time frame: day-7). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2023; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in